CoChat
Sign Up
Cited by 19Cervical Cancer and HPV ResearchReproductive tract infections researchGenital Health and Disease

Association Study between Cervical Lesions and Single or Multiple Vaccine-Target and Non-Vaccine Target Human Papillomavirus (HPV) Types in Women from Northeastern Brazil

Open access
Chagas, Bárbara Simas, Comar, Manola, Gurgel, Ana Pavla Almeida Diniz, Paiva, Sérgio, Seraceni, Silva, de Freitas, Antonio Carlos, Crovella, Sergio·2015·PLOS ONE
DOI 10.1371/journal.pone.0132570PMC PMC4503727
Open this paper in CoChat — free accountOpen PDF

Abstract

We performed an association between high-grade squamous intraepithelial lesions (HSIL), low-grade squamous intraepithelial lesions (LSIL) and single or multiple vaccine-target as well as non-vaccine target Human papillomavirus (HPV) types. Using bead-based HPV genotyping, 594 gynecological samples were genotyped. An association between squamous intraepithelial lesion (SIL) and presence of HPV16, 18, 31, 58 and 56 types were calculated. The risk was estimated by using odds ratio (OR) and 95% of confidence intervals (CI). A total of 370 (62.3%) women were HPV positive. Among these, 157 (42.7%) presented a single HPV infection, and 212 (57.3%) were infected by more than one HPV type. HPV31 was the most prevalent genotype, regardless single and multiple HPV infections. Single infection with HPV31 was associated with LSIL (OR=2.32; 95%CI: 1.01 to 5.32; p=0.04); HPV31 was also associated with LSIL (OR=3.28; 95%CI: 1.74 to 6.19; p= 0.0002) and HSIL (OR=3.82; 95%CI: 2.10 to 6.97; p<0.001) in multiple HPV infections. Risk to harbor cervical lesions was observed in multiple HPV infections with regard to the HPV56 (OR=5.39; 95%CI: 2.44 to 11.90; p<0.001for LSIL; OR=5.37; 95%CI: 2.71 to 10.69; p<0.001) and HPV58 (OR=3.29; 95%CI: 1.34 to 8.09; p=0.0091 for LSIL; OR=3.55; 95%CI: 1.56 to 8.11; p=0.0026) genotypes. In addition, women coinfected with HPV16/31/56 types had 6 and 5-fold increased risk of HSIL (OR=6.46; 95%CI: 1.89 to 22.09; p=0.002) and LSIL (OR=5.22; 95%CI: 1.10 to 24.70; p=0.03), respectively. Multiple HPV infections without HPV16/18 has 2-fold increased risk of HSIL (OR=2.57; 95%CI: 1.41 to 4.70; p=0.002) and LSIL OR=2.03; 95%CI: 1.08 to 3.79; p=0.02). The results of this study suggest that single and multiple vaccine target as well as non-vaccine target HPV types are associated with LSIL and HSIL. These finding should be taken into consideration in the design of HPV vaccination strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0132570

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. [1]Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011; 10.1093/annonc/mdr015 21471563 · DOI
  2. [2]Zur Hausen H. Papillomaviruses in the causation of human cancers—a brief historical account. Virology. 2009; 384: 260– 265. 10.1016/j.virol.2008.11.046 19135222 · DOI · Paper page
  3. [3]De Freitas AC, Gurgel APAD, Chagas BS, Coimbra EC, do Amaral CMM. Susceptibility to cervical cancer: An overview. Gynecol Oncol. 2012; 126: 304– 311. 10.1016/j.ygyno.2012.03.047 22484226 · DOI
  4. [4]Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2: 342– 350. 10.1038/nrc798 12044010 · DOI
  5. [5]De Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7: 453– 459. 10.1016/S1473-3099(07)70158-5 17597569 · DOI · Paper page
  6. [6]De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11: 1048– 1056. 10.1016/S1470-2045(10)70230-8 20952254 · DOI · Paper page
  7. [7]De Vincenzo R, Ricci C, Conte C, Scambia G. HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol Oncol. 2013; 130: 642– 651. 10.1016/j.ygyno.2013.05.033 23747835 · DOI
  8. [8]Nielsen A, Kjaer SK, Munk C, Iftner T. Type-Specific HPV Infection and Multiple HPV Types: Prevalence and Risk Factor Profile in Nearly 12,000 Younger and Older Danish Women: Sex Transm Dis. 2008; 35: 276– 282. 10.1097/OLQ.0b013e31815ac5c7 18091564 · DOI
  9. [9]Ah Lee S, Kang D, Soo Seo S, Kim Jeong J, Young Yoo K, Tark Jeon Y, et al Multiple HPV infection in cervical cancer screened by HPVDNAChipTM. Cancer Lett. 2003; 198: 187– 192. 10.1016/S0304-3835(03)00312-4 12957357 · DOI
  10. [10]Mejlhede N, Bonde J, Fomsgaard A. High frequency of multiple HPV types in cervical specimens from Danish women. APMIS. 2009; 117: 108– 114. 10.1111/j.1600-0463.2008.00019.x 19239432 · DOI
  11. [11]Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, et al Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol. 2004; 57: 68– 72. 10.1136/jcp.57.1.68 14693839 PMC1770158 · DOI
  12. [12]Dickson EL, Vogel RI, Bliss RL, Downs LS. Multiple-Type Human Papillomavirus (HPV) Infections: A Cross-Sectional Analysis of the Prevalence of Specific Types in 309,000 Women Referred for HPV Testing at the Time of Cervical Cytology. Int J Gynecol Cancer. 2013; 23: 1295– 1302. 10.1097/IGC.0b013e31829e9fb4 23970156 PMC3882063 · DOI
  13. [13]Dickson EL, Vogel RI, Geller MA, Downs LS Jr.. Cervical cytology and multiple type HPV infection: A study of 8182 women ages 31–65. Gynecol Oncol. 2014; 133: 405– 408. 10.1016/j.ygyno.2014.03.552 24657488 PMC4040336 · DOI
  14. [14]Carozzi F, Ronco G, Gillio-Tos A, Marco LD, Mistro AD, Girlando S, et al Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. Eur J Cancer. 2012; 48: 1633– 1637. 10.1016/j.ejca.2011.10.010 22088483 · DOI
  15. [15]Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011; 128: 927– 935. 10.1002/ijc.25396 20473886 · DOI
  16. [16]Chaturvedi AK, Katki HA, Hildesheim A, Rodríguez AC, Quint W, Schiffman M, et al Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011; 203: 910– 920. 10.1093/infdis/jiq139 21402543 PMC3068034 · DOI · Paper page
  17. [18]Beca F, Pinheiro J, Rios E, Pontes P, Amendoeira I. Genotypes and prevalence of HPV single and multiple concurrent infections in women with HSIL. Diagn Cytopathol. 2014; 42: 919– 923. 10.1002/dc.23143 24623593 · DOI
  18. [19]Gurgel APAD, Chagas BS, do Amaral CMM, Albuquerque EMB, Serra IGSS, Silva Neto J da C, et al Prevalence and genetic variability in capsid L1 gene of rare human papillomaviruses (HPV) found in cervical lesions of women from North-East Brazil. BioMed Res Int. 2013; 2013: 546354 10.1155/2013/546354 23865057 PMC3705854 · DOI
  19. [20]Baldez da Silva MFPT, Chagas BS, Guimarães V, Katz LMC, Felix PM, Miranda PM, et al HPV31 and HPV33 incidence in cervical samples from women in Recife, Brazil. Genet Mol Res GMR. 2009; 8: 1437– 1443. 10.4238/vol8-4gmr677 20013657 · DOI
  20. [21]Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, et al Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2006; 15: 1274– 1280. 10.1158/1055-9965.EPI-06-0129 16835323 · DOI · Paper page
  21. [22]Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13: 100– 110. 10.1016/S1470-2045(11)70287-X 22075170 · DOI
  22. [23]Malagón T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, et al Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12: 781– 789. 10.1016/S1473-3099(12)70187-1 22920953 · DOI
  23. [24]Goldstone SE, Jessen H, Palefsky JM, Giuliano AR, Moreira ED Jr., Vardas E, et al Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine. 2013; 31: 3849– 3855. 10.1016/j.vaccine.2013.06.057 23831322 · DOI
  24. [25]Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13: 89– 99. 10.1016/S1470-2045(11)70286-8 22075171 · DOI
  25. [26]Hildesheim A, Wacholder S, Catteau G, Struyf F, Dubin G, Herrero R. Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine. 2014; 32: 5087– 5097. 10.1016/j.vaccine.2014.06.038 25018097 PMC4166498 · DOI
  26. [27]Kavanagh K, Pollock KGJ, Potts A, Love J, Cuschieri K, Cubie H, et al Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014; 110: 2804– 2811. 10.1038/bjc.2014.198 24736582 PMC4037824 · DOI
  27. [28]Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Liu B, Bateson D, et al Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014; 14: 958– 966. 10.1016/S1473-3099(14)70841-2 25107680 · DOI · Paper page
  28. [29]Cómbita A, Duarte D, Rodríguez J, Molano M, Martínez L, Romero P, et al Evaluation of the immune response to human papillomavirus types 16, 18, 31, 45 and 58 in a group of Colombian women vaccinated with the quadrivalent vaccine. Rev Colomb Cancerol. 2013; 17: 103– 110. 10.1016/S0123-9015(13)70012-X · DOI
  29. [30]Kahn JA, Brown DR, Ding L, Widdice LE, Shew ML, Glynn S, et al Vaccine-Type Human Papillomavirus and Evidence of Herd Protection After Vaccine Introduction. Pediatrics. 2012; peds. 2011– 3587. 10.1542/peds.2011-3587 PMC3408690 22778297 · DOI
  30. [31]Orlando PA, Gatenby RA, Giuliano AR, Brown JS. Evolutionary Ecology of Human Papillomavirus: Trade-offs, Coexistence, and Origins of High-Risk and Low-Risk Types. J Infect Dis. 2012; 205: 272– 279. 10.1093/infdis/jir717 22090448 PMC3244363 · DOI
  31. [32]Gheit T, Landi S, Gemignani F, Snijders PJF, Vaccarella S, Franceschi S, et al Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol. 2006; 44: 2025– 2031. 10.1128/JCM.02305-05 16757593 PMC1489390 · DOI
  32. [33]Comar M, Iannacone MR, Casalicchio G, McKay-Chopin S, Tommasino M, Gheit T. Comparison of hybrid capture II, linear array, and a bead-based multiplex genotyping assay for detection of human papillomavirus in women with negative pap test results and atypical squamous cells of undetermined significance. J Clin Microbiol. 2012; 50: 4041– 4046. 10.1128/JCM.02105-12 23035194 PMC3502951 · DOI
  33. [34]Munagala R, Donà MG, Rai SN, Jenson AB, Bala N, Ghim SJ, et al Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int J Oncol. 2009; 34: 263– 271. 19082497
  34. [35]Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006; 24 Suppl 1: S1– 15. 10.1016/j.vaccine.2005.09.054 16406226 · DOI
  35. [36]Pista A, Oliveira A, Verdasca N, Ribeiro F. Single and multiple human papillomavirus infections in cervical abnormalities in Portuguese women. Clin Microbiol Infect. 2011; 17: 941– 946. 10.1111/j.1469-0691.2010.03387.x 21040156 · DOI
  36. [37]Baldez da Silva MFPT, Guimarães V, Silva MAR, Medeiros do Amaral CM, Beçak W, Stocco RC, et al Frequency of human papillomavirus types 16, 18, 31, and 33 and sites of cervical lesions in gynecological patients from Recife, Brazil. Genet Mol Res GMR. 2012; 11: 462– 466. 10.4238/2012.March.1.3 22427039 · DOI
  37. [38]de M Fernandes TAA, de V Meissner R, Bezerra LF, de Azevedo PRM, Fernandes JV. Human papillomavirus infection in women attended at a cervical cancer screening service in Natal, Brazil. Braz J Microbiol. 2008; 39: 573– 578. 10.1590/S1517-83822008000300031 24031268 PMC3768430 · DOI
  38. [39]Castro MM, Farias IP, Borborema-Santos CM, Correia G, Astolfi-Filho S. Prevalence of human papillomavirus (HPV) type 16 variants and rare HPV types in the central Amazon region. Genet Mol Res GMR. 2011; 10: 186– 196. 10.4238/vol10-1gmr992 21341210 · DOI
  39. [40]Veríssimo Fernandes J, de Vasconcellos Meissner R, Goretti Freire Carvalho M, Araújo de Medeiros Fernandes TA, Medeiros Azevedo PR, Weber Veríssimo de Azevedo J, et al Human papillomavirus prevalence in women with normal cytology and with cervical cancer in Natal, Brazil. Mol Med Rep. 2011; 4: 1321– 1326. 10.3892/mmr.2011.579 21887467 · DOI
  40. [41]Alencar TR, Cerqueira DM, Cruz MR da, Wyant PS, Ramalho ED, Martins CRF. New HPV-16 European and non-European variants in Central Brazil. Virus Genes. 2006; 35: 1– 4. 10.1007/s11262-006-0040-5 17048111 · DOI
  41. [42]Cruz MR, Cerqueira DM, Cruz WB, Camara GNL, Brígido MM, Silva EO, et al Prevalence of human papillomavirus type 16 variants in the Federal District, Central Brazil. Mem Inst Oswaldo Cruz. 2004; 99: 281– 282. /S0074-02762004000300007 15273800
  42. [43]Fernandes JV, Meissner RV, Carvalho MG, Fernandes TA, Azevedo PR, Sobrinho JS, et al Prevalence of human papillomavirus in archival samples obtained from patients with cervical pre-malignant and malignant lesions from Northeast Brazil. BMC Res Notes. 2010; 3: 96 10.1186/1756-0500-3-96 20377903 PMC2857859 · DOI
  43. [44]de M Fernandes TAA, de V Meissner R, Bezerra LF, de Azevedo PRM, Fernandes JV. Human papillomavirus infection in women attended at a cervical cancer screening service in Natal, Brazil. Braz J Microbiol. 2008; 39: 573– 578. 10.1590/S1517-83822008000300031 24031268 PMC3768430 · DOI
  44. [45]Freitas LB, Chen Z, Muqui EF, Boldrini NAT, Miranda AE, Spano LC, et al Human Papillomavirus 16 Non-European Variants Are Preferentially Associated with High-Grade Cervical Lesions. PLoS ONE. 2014; 9: e100746 10.1371/journal.pone.0100746 24983739 PMC4077691 · DOI
  45. [46]Chagas BS, Batista MV de A, Crovella S, Gurgel APAD, Silva Neto J da C, Serra IGSS, et al Novel E6 and E7 oncogenes variants of human papillomavirus type 31 in Brazilian women with abnormal cervical cytology. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2013; 16: 13– 18. 10.1016/j.meegid.2013.02.001 23403356 · DOI
  46. [47]Chagas BS, Batista MVA, Guimarães V, Balbino VQ, Crovella S, Freitas AC. New variants of E6 and E7 oncogenes of human papillomavirus type 31 identified in Northeastern Brazil. Gynecol Oncol. 2011; 123: 284– 288. 10.1016/j.ygyno.2011.07.008 21802716 · DOI
  47. [48]Berumen J, Ordoñez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, et al Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J Natl Cancer Inst. 2001; 93: 1325– 1330. 11535707
  48. [49]Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013; 445: 232– 243. 10.1016/j.virol.2013.07.018 23998342 PMC3979972 · DOI
  49. [50]Burk RD, Terai M, Gravitt PE, Brinton LA, Kurman RJ, Barnes WA, et al Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res. 2003; 63: 7215– 7220. 14612516
  50. [51]Burroni E, Bisanzi S, Sani C, Puliti D, Carozzi F. Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix. J Med Virol. 2013; 85: 83– 90. 10.1002/jmv.23417 23124863 · DOI
  51. [52]Chang Y-J, Chen H-C, Lee B-H, You S-L, Lin C-Y, Pan M-H, et al Unique variants of human papillomavirus genotypes 52 and 58 and risk of cervical neoplasia. Int J Cancer J Int Cancer. 2011; 129: 965– 973. 10.1002/ijc.25724 20949622 · DOI
  52. [53]Chansaenroj J, Theamboonlers A, Junyangdikul P, Swangvaree S, Karalak A, Poovorawan Y. Whole genome analysis of human papillomavirus type 16 multiple infection in cervical cancer patients. Asian Pac J Cancer Prev APJCP. 2012; 13: 599– 606. 22524831
  53. [54]Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS, et al Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. J Virol. 2012; 86: 6855– 6861. 10.1128/JVI.00483-12 22491459 PMC3393538 · DOI
  54. [55]Cornet I, Gheit T, Clifford GM, Combes J-D, Dalstein V, Franceschi S, et al Human papillomavirus type 16 E6 variants in France and risk of viral persistence. Infect Agent Cancer. 2013; 8: 4 10.1186/1750-9378-8-4 23343041 PMC3562255 · DOI
  55. [56]Gheit T, Cornet I, Clifford GM, Iftner T, Munk C, Tommasino M, et al Risks for persistence and progression by human papillomavirus type 16 variant lineages among a population-based sample of Danish women. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2011; 20: 1315– 1321. 10.1158/1055-9965.EPI-10-1187 21527576 · DOI
  56. [57]Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer J Int Cancer. 1996; 69: 364– 368. 10.1002/(SICI)1097-0215(19961021)69:5<364::AID-IJC2>3.0.CO;2-3 8900368 · DOI
  57. [58]Quint KD, de Koning MNC, van Doorn L-J, Quint WGV, Pirog EC. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol. 2010; 117: 297– 301. 10.1016/j.ygyno.2010.02.003 20207397 · DOI
  58. [59]Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, et al A Population-Based Prospective Study of Carcinogenic Human Papillomavirus Variant Lineages, Viral Persistence, and Cervical Neoplasia. Cancer Res. 2010; 70: 3159– 3169. 10.1158/0008-5472.CAN-09-4179 20354192 PMC2855741 · DOI
  59. [60]Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, et al High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer J Int Cancer. 2007; 120: 1763– 1768. 10.1002/ijc.22481 17230525 · DOI
  60. [61]Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, et al Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol. 2000; 81: 2959– 2968. 11086127
  61. [62]Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, et al Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol. 1997; 71: 2463– 2472. 9032384 PMC191357
  62. [63]Zehbe I, Lichtig H, Westerback A, Lambert PF, Tommasino M, Sherman L. Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential. Mol Cancer. 2011; 10: 77 10.1186/1476-4598-10-77 21702904 PMC3144020 · DOI
  63. [64]Zuna RE, Tuller E, Wentzensen N, Mathews C, Allen RA, Shanesmith R, et al HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer. Infect Agent Cancer. 2011; 6: 19 10.1186/1750-9378-6-19 22035468 PMC3226431 · DOI
  64. [65]Xi LF, Demers GW, Koutsky LA, Kiviat NB, Kuypers J, Watts DH, et al Analysis of Human Papillomavirus Type 16 Variants Indicates Establishment of Persistent Infection. J Infect Dis. 1995; 172: 747– 755. 7658068
  65. [66]Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, et al Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst. 2006; 98: 1045– 1052. 10.1093/jnci/djj297 16882941 · DOI
  66. [67]Gurgel APAD, Chagas B, Simas R, do Amaral CM, Nascimento KC, et al Prevalence of Human Papillomavirus Variants and Genetic Diversity in the L1 Gene and Long Control Region of HPV16, HPV31, and HPV58 Found in North-East Brazil. BioMed Res Int. 2015; 2015: e130828 10.1155/2015/130828 PMC4352477 25793187 · DOI
  67. [68]Schmitt M, Bravo IG, Snijders PJF, Gissmann L, Pawlita M, Waterboer T. Bead-Based Multiplex Genotyping of Human Papillomaviruses. J Clin Microbiol. 2006; 44: 504– 512. 10.1128/JCM.44.2.504-512.2006 16455905 PMC1392679 · DOI

Cited by

Sorted by citations

Authors
Chagas, B. S., Comar, M., Gurgel, A. P. A. D., Paiva, S., Seraceni, S., de Freitas, A. C., & Crovella, S.
Affiliations
  • Universidade Federal de Pernambuco (BR)
  • IRCCS Materno Infantile Burlo Garofolo (IT)
  • University of Trieste (IT)
ORCID
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2015-07-15
Volume
10
Issue
7
Pages
e0132570
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0132570
PMC
PMC4503727
OpenAlex
W1413250268
Cited by
19
References
1
Citations by year
2025: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 4 · 2018: 4 · 2017: 3 · 2016: 3
FWCI
2.62
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
Funders
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Surgery › Genital Health and Disease
Keywords
human papillomavirus, cervical lesions, squamous intraepithelial lesions, HPV genotyping, multiple HPV infection, HPV16, HPV 18, HPV 31, HPV 56, HPV58, HPV35, HPV39, HPV 59, HPV52, HPV51, HPV53, HPV54, HPV68, HPV70, HPV73, HPV81, HPV84
MeSH terms
Adult, Brazil, Uterine Cervical Dysplasia, Female, Humans, Risk Factors, Papillomaviridae, Papillomavirus Infections, Papillomavirus Vaccines, Squamous Intraepithelial Lesions of the Cervix

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review